Lifecore Biomedical Inc. (NASDAQ:LFCR) — Market Cap & Net Worth
Market Cap & Net Worth: Lifecore Biomedical Inc. (LFCR)
Lifecore Biomedical Inc. (NASDAQ:LFCR) has a market capitalization of $200.68 Million ($200.68 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16635 globally and #3887 in its home market, demonstrating a -3.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lifecore Biomedical Inc.'s stock price $5.35 by its total outstanding shares 37509407 (37.51 Million). Review total liabilities of Lifecore Biomedical Inc. to assess the company's total debt and financial obligations.
Lifecore Biomedical Inc. Market Cap History: 2015 to 2026
Lifecore Biomedical Inc.'s market capitalization history from 2015 to 2026. Data shows change from $443.74 Million to $200.68 Million (-7.58% CAGR).
Index Memberships
Lifecore Biomedical Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.01% | #458 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1636 of 3165 |
Weight: Lifecore Biomedical Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lifecore Biomedical Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lifecore Biomedical Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.38x
Lifecore Biomedical Inc.'s market cap is 2.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $517.63 Million | $541.10 Million | -$11.64 Million | 0.96x | N/A |
| 2017 | $472.62 Million | $532.26 Million | $10.59 Million | 0.89x | 44.63x |
| 2018 | $444.11 Million | $524.23 Million | $24.83 Million | 0.85x | 17.89x |
| 2019 | $424.23 Million | $557.56 Million | $2.12 Million | 0.76x | 199.92x |
| 2020 | $406.98 Million | $160.07 Million | -$38.19 Million | 2.54x | N/A |
| 2021 | $416.35 Million | $100.87 Million | -$32.29 Million | 4.13x | N/A |
| 2022 | $243.06 Million | $185.79 Million | -$97.43 Million | 1.31x | N/A |
| 2023 | $232.18 Million | $111.27 Million | -$116.72 Million | 2.09x | N/A |
| 2024 | $278.69 Million | $128.26 Million | $12.01 Million | 2.17x | 23.20x |
| 2025 | $306.83 Million | $128.87 Million | -$38.72 Million | 2.38x | N/A |
Competitor Companies of LFCR by Market Capitalization
Companies near Lifecore Biomedical Inc. in the global market cap rankings as of June 17, 2026.
Key companies related to Lifecore Biomedical Inc. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Lifecore Biomedical Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Lifecore Biomedical Inc.'s market cap moved from $443.74 Million to $ 200.68 Million, with a yearly change of -7.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $200.68 Million | -34.60% |
| 2025 | $306.83 Million | +10.09% |
| 2024 | $278.69 Million | +20.03% |
| 2023 | $232.18 Million | -4.48% |
| 2022 | $243.06 Million | -41.62% |
| 2021 | $416.35 Million | +2.30% |
| 2020 | $406.98 Million | -4.07% |
| 2019 | $424.23 Million | -4.48% |
| 2018 | $444.11 Million | -6.03% |
| 2017 | $472.62 Million | -8.70% |
| 2016 | $517.63 Million | +16.65% |
| 2015 | $443.74 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Lifecore Biomedical Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $200.68 Million USD |
| MoneyControl | $200.68 Million USD |
| MarketWatch | $200.68 Million USD |
| marketcap.company | $200.68 Million USD |
| Reuters | $200.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more